S&P 500   3,160.48 (+0.60%)
DOW   28,049.01 (+0.49%)
QQQ   205.95 (+0.47%)
AAPL   270.15 (-0.23%)
FB   201.05 (-0.60%)
MSFT   152.16 (+0.30%)
GOOGL   1,345.57 (+0.10%)
AMZN   1,753.90 (+0.30%)
CGC   20.79 (+2.67%)
MU   50.72 (+2.96%)
GE   11.37 (+3.65%)
TSLA   359.61 (+1.96%)
T   38.44 (+0.71%)
AMD   41.24 (+4.48%)
ACB   2.55 (+4.08%)
F   9.28 (+1.87%)
PRI   136.70 (+0.92%)
NFLX   296.72 (-0.74%)
BAC   34.41 (+2.29%)
DIS   147.57 (-0.01%)
S&P 500   3,160.48 (+0.60%)
DOW   28,049.01 (+0.49%)
QQQ   205.95 (+0.47%)
AAPL   270.15 (-0.23%)
FB   201.05 (-0.60%)
MSFT   152.16 (+0.30%)
GOOGL   1,345.57 (+0.10%)
AMZN   1,753.90 (+0.30%)
CGC   20.79 (+2.67%)
MU   50.72 (+2.96%)
GE   11.37 (+3.65%)
TSLA   359.61 (+1.96%)
T   38.44 (+0.71%)
AMD   41.24 (+4.48%)
ACB   2.55 (+4.08%)
F   9.28 (+1.87%)
PRI   136.70 (+0.92%)
NFLX   296.72 (-0.74%)
BAC   34.41 (+2.29%)
DIS   147.57 (-0.01%)
S&P 500   3,160.48 (+0.60%)
DOW   28,049.01 (+0.49%)
QQQ   205.95 (+0.47%)
AAPL   270.15 (-0.23%)
FB   201.05 (-0.60%)
MSFT   152.16 (+0.30%)
GOOGL   1,345.57 (+0.10%)
AMZN   1,753.90 (+0.30%)
CGC   20.79 (+2.67%)
MU   50.72 (+2.96%)
GE   11.37 (+3.65%)
TSLA   359.61 (+1.96%)
T   38.44 (+0.71%)
AMD   41.24 (+4.48%)
ACB   2.55 (+4.08%)
F   9.28 (+1.87%)
PRI   136.70 (+0.92%)
NFLX   296.72 (-0.74%)
BAC   34.41 (+2.29%)
DIS   147.57 (-0.01%)
S&P 500   3,160.48 (+0.60%)
DOW   28,049.01 (+0.49%)
QQQ   205.95 (+0.47%)
AAPL   270.15 (-0.23%)
FB   201.05 (-0.60%)
MSFT   152.16 (+0.30%)
GOOGL   1,345.57 (+0.10%)
AMZN   1,753.90 (+0.30%)
CGC   20.79 (+2.67%)
MU   50.72 (+2.96%)
GE   11.37 (+3.65%)
TSLA   359.61 (+1.96%)
T   38.44 (+0.71%)
AMD   41.24 (+4.48%)
ACB   2.55 (+4.08%)
F   9.28 (+1.87%)
PRI   136.70 (+0.92%)
NFLX   296.72 (-0.74%)
BAC   34.41 (+2.29%)
DIS   147.57 (-0.01%)
Log in

NASDAQ:EVOK - Evoke Pharma Stock Price, Forecast & News

$1.60
-0.04 (-2.44 %)
(As of 12/12/2019 01:25 PM ET)
Today's Range
$1.60
Now: $1.60
$1.63
50-Day Range
$0.83
MA: $1.22
$1.68
52-Week Range
$0.50
Now: $1.60
$3.26
Volume2,810 shs
Average Volume536,412 shs
Market Capitalization$38.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.23 per share

Profitability

Net Income$-7,570,000.00

Miscellaneous

Employees6
Market Cap$38.77 million
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.


Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) released its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.02. View Evoke Pharma's Earnings History.

When is Evoke Pharma's next earnings date?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Evoke Pharma.

What price target have analysts set for EVOK?

2 Wall Street analysts have issued 12-month target prices for Evoke Pharma's shares. Their forecasts range from $1.33 to $5.00. On average, they expect Evoke Pharma's share price to reach $3.17 in the next twelve months. This suggests a possible upside of 97.8% from the stock's current price. View Analyst Price Targets for Evoke Pharma.

What is the consensus analysts' recommendation for Evoke Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evoke Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evoke Pharma.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (12/4/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology and risks. We remain in a holding pattern until further clarity is obtained regarding the issues raised in the CRL and the degree to which they can be addressed near-term, as well as the timeline to potential resubmission of the Gimoti NDA and possible regulatory approval of the drug." (8/9/2019)

Has Evoke Pharma been receiving favorable news coverage?

Press coverage about EVOK stock has trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Evoke Pharma earned a coverage optimism score of -3.1 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Evoke Pharma.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 681,400 shares, an increase of 39.3% from the October 31st total of 489,200 shares. Based on an average daily volume of 144,500 shares, the short-interest ratio is currently 4.7 days. Currently, 3.2% of the shares of the stock are sold short. View Evoke Pharma's Current Options Chain.

Who are some of Evoke Pharma's key competitors?

What other stocks do shareholders of Evoke Pharma own?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. David A. Gonyer, Co-Founder, CEO, Pres & Director (Age 55)
  • Mr. Matthew J. D'Onofrio, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 49)
  • Dr. Marilyn R. Carlson, Chief Medical Officer (Age 71)

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.60.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $38.77 million. The specialty pharmaceutical company earns $-7,570,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Evoke Pharma employs 6 workers across the globe.View Additional Information About Evoke Pharma.

What is Evoke Pharma's official website?

The official website for Evoke Pharma is http://www.evokepharma.com/.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (NASDAQ EVOK)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: 12b-1 Fees

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel